Comprehensive B Cell Phenotyping Profile for Chronic Graft-Versus-Host Disease Diagnosis

Chronic graft-versus-host disease (cGvHD) is now the leading cause of late non-relapse mortality and morbidity following allogeneic hematopoietic cell transplantation (HCT) [1]. The pathogenic role of B cells in cGvHD was first identified in murine models in 1995 [2]. The role of abnormalities in B cell function have been confirmed in humans due to the successful use of B cell directed therapies such as rituximab [3] and approval of the first FDA approved drug for cGvHD therapy, ibrutinib [4].

Source: Biology of Blood and Marrow Transplantation - November 14, 2018 Category: Hematology Authors: Jacob Rozmus, Amina Kariminia, Sayeh Abdossamadi, Barry E. Storer, Paul J. Martin, Stephanie J. Lee, Daniel Wolff, Mukta Arora, Corey Cutler, Kirk R. Schultz Source Type: research